Skip to main content
. 2008 Feb 19;98(6):1053–1058. doi: 10.1038/sj.bjc.6604273

Table 2. Clinical response to 131I-MIBG therapy.

Characteristic Total (%)
Biochemical markers (24 h urine 5-HIAA and/or serum chromogranin A) measured before and after 131I-MIBG treatment 29
>50% reduction of biochemical markers post-131I-MIBG therapy 11/29 (36.7)
Radiological investigations performed before and after 131I-MIBG treatment 40
>25% reduction in tumour size demonstrated on post-131I-MIBG scans 11/40 (27.5)
Symptomatic response to 131I-MIBG therapy 27/48 (56.2)